Yhdeltä kilpailijalta taas huonoja faasin II tuloksia: https://www.fiercebiotech.com/biotech/cerevance-fails-phase-2-trial-early-untreated-parkinsons. Tämä on tosin perinteisesti taas esitetty positiivisessa valossa. Tuo Cerevancen lääkeaine, Solengepras, ei ole käsittääkseni vaikutusmekanismiltaan verrattavissa HER-096:een.
“Cerevance reported data from the phase 2 monotherapy study Tuesday. Solengepras was statistically no better than placebo on the MDS-UPDRS Parkinson’s clinical rating scale at Week 12, causing the trial to miss its primary endpoint.”
“The primary endpoint of the phase 3 adjunctive therapy trial is looking at motor symptoms as reported in patient diaries. Several of the secondary endpoints also capture patient-reported measures. As such, Thompson’s reading of the phase 2 trial manages to frame the failure in a positive light for the phase 3.”